Effect of Bala Arka in elevated serum uric acid level
Phase 3
- Conditions
- Health Condition 1: E799- Disorder of purine and pyrimidinemetabolism, unspecified
- Registration Number
- CTRI/2023/08/056949
- Lead Sponsor
- Dr Neena Noble
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Participants with elevated serum uric acid beyond the level of 6.8 mg/dl.
Age between 25-60 yrs
Patients irrespective of gender
Patients willing to give informed consent.
Exclusion Criteria
Secondary gout
Joint Deformities
Inflammatory joint disorders like RA, Reactive arthritis.
Pregnant and lactating mother
Known cases of Gastritis
Known case of other systemic illness
Known case of Psychiatric illness
Known case of Malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Uric acidTimepoint: Serum uric acid levels will be assessed on 0th & 31st day with intervention & on 45th day without intervention.
- Secondary Outcome Measures
Name Time Method Tenderness <br/ ><br>Pain <br/ ><br>Swelling <br/ ><br>DiscolourationTimepoint: 45 days